Drug Information

Drug General Information
Drug ID
D0RJ1W
Former ID
DIB004174
Drug Name
OX-914
Indication Asthma [ICD10:J45] Phase 2 [522443]
Company
Inflazyme Pharmaceuticals
Target and Pathway
Target(s) CAMP-specific 3',5'-cyclic phosphodiesterase 4B Target Info Inhibitor [549827]
Type IV phosphodiesterase Target Info Inhibitor [549827]
CAMP-specific 3',5'-cyclic phosphodiesterase 4A Target Info Inhibitor [549827]
KEGG Pathway Purine metabolism
cAMP signaling pathway
Morphine addictionhsa00230:Purine metabolism
Morphine addiction
NetPath Pathway IL5 Signaling Pathway
IL2 Signaling Pathway
PathWhiz Pathway Purine Metabolism
Reactome DARPP-32 events
G alpha (s) signalling eventsR-HSA-180024:DARPP-32 events
G alpha (s) signalling events
WikiPathways G Protein Signaling Pathways
Myometrial Relaxation and Contraction Pathways
Nuclear Receptors Meta-Pathway
Opioid SignallingWP35:G Protein Signaling Pathways
TSH signaling pathwayWP35:G Protein Signaling Pathways
References
Ref 522443ClinicalTrials.gov (NCT00758446) Efficacy and Safety Study of BLX-028914 in Subjects With Allergic Rhinitis. U.S. National Institutes of Health.
Ref 549827Orexo announces Phase IIa data on OX914 in rhinitis. Orexo. 24th March, 2009.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.